

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3484604

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>SEQUENCE:</b>	2

**CONVEYING PARTY DATA**

Name	Execution Date
COHEREX MEDICAL, INC.	08/14/2015

**RECEIVING PARTY DATA**

<b>Name:</b>	GENERAL ELECTRIC CAPITAL CORPORATION
<b>Street Address:</b>	TWO BETHESDA METRO CENTER SUITE 600
<b>City:</b>	BETHESDA
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20814

**PROPERTY NUMBERS Total: 35**

Property Type	Number
Patent Number:	8845711
Patent Number:	8690911
Patent Number:	8795328
Patent Number:	8840641
Patent Number:	8636764
Patent Number:	8715318
Patent Number:	8979941
Patent Number:	8840655
Patent Number:	8864809
Patent Number:	8167894
Patent Number:	8529597
Patent Number:	8221405
Patent Number:	8402974
Patent Number:	8235988
Patent Number:	8636732
Patent Number:	9044233
Patent Number:	8235885
Patent Number:	8540616
Patent Number:	8579791

PATENT

Property Type	Number
Patent Number:	8845509
Application Number:	12818041
Application Number:	12818059
Application Number:	13450755
Application Number:	13666612
Application Number:	14308695
Application Number:	62148317
Application Number:	14163925
Application Number:	14215266
Application Number:	14287103
Application Number:	14487885
Application Number:	11836000
Application Number:	11836016
Application Number:	14023462
Application Number:	14715338
Application Number:	14500811

**CORRESPONDENCE DATA**

**Fax Number:** (214)964-9501

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2149649427

**Email:** tatyana.rozenberg@hklaw.com

**Correspondent Name:** TATYANA ROZENBERG

**Address Line 1:** HOLLAND & KNIGHT LLP

**Address Line 2:** 200 CRESCENT COURT, SUITE 1600

**Address Line 4:** DALLAS, TEXAS 75201

**NAME OF SUBMITTER:** TATYANA ROZENBERG

**SIGNATURE:** /Tatyana Rozenberg/

**DATE SIGNED:** 08/14/2015

**Total Attachments: 18**

source=Coherex IP Security Agreement#page1.tif  
source=Coherex IP Security Agreement#page2.tif  
source=Coherex IP Security Agreement#page3.tif  
source=Coherex IP Security Agreement#page4.tif  
source=Coherex IP Security Agreement#page5.tif  
source=Coherex IP Security Agreement#page6.tif  
source=Coherex IP Security Agreement#page7.tif  
source=Coherex IP Security Agreement#page8.tif  
source=Coherex IP Security Agreement#page9.tif  
source=Coherex IP Security Agreement#page10.tif

source=Coherex IP Security Agreement#page11.tif  
source=Coherex IP Security Agreement#page12.tif  
source=Coherex IP Security Agreement#page13.tif  
source=Coherex IP Security Agreement#page14.tif  
source=Coherex IP Security Agreement#page15.tif  
source=Coherex IP Security Agreement#page16.tif  
source=Coherex IP Security Agreement#page17.tif  
source=Coherex IP Security Agreement#page18.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the “**Agreement**”), dated as of August 14, 2015, is made by COHEREX MEDICAL, INC., a Delaware Corporation (“**Grantor**”), in favor of GENERAL ELECTRIC CAPITAL CORPORATION (“**GE Capital**”), as agent (in such capacity, together with its successors and assigns in such capacity, the “**Agent**”) for the Lenders (as defined in the Loan Agreement referred to below).

### WITNESSETH:

**WHEREAS**, pursuant to the Loan and Security Agreement, dated as of August 14, 2015 (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the “**Loan Agreement**”), among Grantor, the other Loan Parties (as defined therein) thereto, the lenders from time to time party thereto (the “**Lenders**”) and Agent, the Lenders have severally agreed to make extensions of credit to the Grantor upon the terms and subject to the conditions set forth therein; and

**WHEREAS**, pursuant to the Loan Agreement, Grantor is required to execute and deliver this Agreement;

**NOW, THEREFORE**, in consideration of the premises and mutual covenants herein contained and to induce Agent and the Lenders to enter into the Loan Agreement and to induce the Lenders to make their respective extensions of credit to Grantor under the Loan Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees with the Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Loan Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations, hereby mortgages, pledges and hypothecates to Agent, for the benefit of itself and Lenders, and grants to Agent, for the benefit of itself and Lenders, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor (the “**Intellectual Property Collateral**”):

(a) all of its trade secrets and rights under any written agreement granting any right to use trade secrets;

(b) all of its copyrights and rights under any written agreement granting any right to use copyrights, including, without limitation, those copyright registrations and applications referred to on Schedule 1 hereto, together with all renewals, reversions and extensions of the foregoing;

(c) all of its trademarks and rights under any written agreement granting any right to use trademarks, including, without limitation, those trademark registrations and applications referred to on Schedule 2 hereto, together with all renewals, reversions and extensions of the foregoing;

(d) all goodwill of the business connected with the use of, and symbolized by, each such trademark covered by clause (c) above;

(e) all of its US patents and rights under any written agreement granting any right to use US patents, including, without limitation, those US patents referred to on Schedule 3 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(f) all of its US patent applications and rights under any written agreement granting any right to use US patent applications, including, without limitation, those applications referred to on Schedule 4 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(g) all of its PCT patent applications and rights under any written agreement granting any right to use PCT patent applications, including, without limitation, those PCT patent applications referred to on Schedule 5 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(h) all of its foreign patents and patent applications, and rights under any written agreement granting any right to use foreign patents and patent applications, including, without limitation, those patent and patent applications referred to on Schedule 6 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(i) all applications, registrations, claims, products, awards, judgments, amendments, improvements and insurance claims related thereto now or hereafter owned or licensed by Grantor, or any claims for damages by way of any past, present, or future infringement of any of the foregoing, together with all accessions and additions thereto, proceeds and products thereof (including, without limitation, any proceeds resulting under insurance policies); provided, further, that the Intellectual Property Collateral shall include, without limitation, all cash, royalty fees, other proceeds, accounts and general intangibles that consist of rights of payment to or on behalf of Grantor or proceeds from the sale, licensing or other disposition of all or any part of, or rights in, the Intellectual Property Collateral by or on behalf of Grantor; and

(j) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Notwithstanding the foregoing and for the avoidance of doubt, the Intellectual Property Collateral shall not include any Excluded Property (as defined in the Loan Agreement).

Section 3. Loan Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with, and is in no way limiting, the security interest granted to Agent, for the benefit of itself and Lenders, pursuant to the Loan Agreement, and Grantor hereby acknowledges and agrees that the rights and remedies of Agent and Lenders with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of each of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall retain full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Intellectual Property subject to a security interest hereunder.

Section 5. Counterparts. This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

Section 6. Governing Law. This Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[Signature Pages Follow]

In witness whereof, Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

GRANTOR:

COHEREX MEDICAL, INC.

By:   
Name: Alex Martin  
Title: Chief Executive Officer and President

[Signatures Continue on Following Page]


[Signature Page to Intellectual Property Security Agreement]

#36621260

**PATENT**  
**REEL: 036332 FRAME: 0910**

ACCEPTED AND AGREED  
as of the date first above written:

**GENERAL ELECTRIC CAPITAL CORPORATION,**  
as Agent

By:   
Name: Jessica Bataille  
Title: Duly Authorized Signatory

[End of Signature Pages]

[Signature Page to Intellectual Property Security Agreement]

#36621260

**PATENT**  
**REEL: 036332 FRAME: 0911**



**Schedule 1  
to  
Intellectual Property Security Agreement**

**Copyrights and Copyright Applications**

None

**Schedule 2**  
**to**  
**Intellectual Property Security Agreement**  
**Trademarks and Trademark Applications**

[See attached]

Coherex Trademark Report

COUNTRY	TRADEMARK	STATUS	APP #	REG #	CLASS	APP DATE	REG DATE	OWNER	DEADLINE	H&H FILE NO.
United States	COHEREX MEDICAL	Registered	78/898,624	3,932,695	10	Jun-1-2006	Mar-15-2011	Coherex Medical, Inc.	15 March 2016 Section 8 & 15 Affidavit Due	Coherex Docket No. T001US
United States	COHEREX WAVECREST	Registered	85/144,841	4,268,716	10	Oct-4-2010	Jan-1-2013	Coherex Medical, Inc.	1 January 2018 Section 8 & 15 Affidavit Due	Coherex Docket No. T007US
United States	WAVECREST	Registered	77/859,220	4,276,082	10	Oct-28-2009	Jan-15-2013	Coherex Medical, Inc.	15 January 2018 Section 8 & 15 Affidavit Due	Coherex Docket No. T006US
United States	COHEREX FLATSTENT	Registered	77/327,245	3,750,287	10	Nov-12-2007	Feb-16-2010	Coherex Medical, Inc.	16 February 2015 to 16 February 2016 Section 8 & 15 Affidavit Due	Coherex Docket No. T003US
Argentina	COHEREX FLATSTENT	Registered	2,934,702	2,368,340	10	Aug-5-2009	May-14-2010	Coherex Medical, Inc.	14 May 2020 Next Renewal Due	59666.0115
Argentina	COHEREX MEDICAL	Registered	2,934,703	2,368,339	10	Aug-5-2009	May-14-2010	Coherex Medical, Inc.	14 May 2020 Next Renewal Due	59666.0111
Argentina	COHEREX WAVECREST	Registered	3,079,907	2512168	10	Apr-14-2011	Jun-29-2012	Coherex Medical, Inc.	29 Jun 2022 Next Renewal Due	59666.0169
Australia	COHEREX FLATSTENT	Registered	1,304,387	1304387	10	Jun-16-2009	Jul-16-2009	Coherex Medical, Inc.	16 Jun 2019 Next Renewal Due	59666.0106
Australia	COHEREX MEDICAL	Registered	007588874	1304386	10	Jun-16-2009	Oct-26-2009	Coherex Medical, Inc.	16 Jun 2019 Next Renewal Due	59666.0101
Australia	COHEREX WAVECREST	Registered	1419015	1419015	10	Apr-8-2011	Nov-17-2011	Coherex Medical, Inc.	8 Apr 2021 Next Renewal Due	59666.0164
Canada	COHEREX FLATSTENT	Registered	1,442,026	TMA830,983	10	Jun-18-2009	Aug-30-2012	Coherex Medical, Inc.	30 Aug 2027 Next Renewal Due	59666.0107
Canada	COHEREX MEDICAL	Registered	1,442,018	TMA857,158	10	Jun-18-2009	Aug-7-2013	Coherex Medical, Inc.	07 Aug 2028 Next Renewal Due	59666.0102
Canada	COHEREX WAVECREST	Pending	1522969			Apr-8-2011		Coherex Medical, Inc.	08 Oct 2015 3rd IU Extension Due (Canada)	59666.0167
Chile	COHEREX FLATSTENT	Registered	873,677	896,060	10	Aug-7-2009	Sep-2-2010	Coherex Medical, Inc.	02 Sep 2020 Next Renewal Due	59666.0117
Chile	COHEREX MEDICAL	Registered	873,678	896,061	10	Aug-7-2009	Sep-2-2010	Coherex Medical, Inc.	02 Sep 2020 Next Renewal Due	59666.0113
Chile	COHEREX WAVECREST	Registered	948569	940900	10	Apr-11-2011	Dec-20-2011	Coherex Medical, Inc.	20 Dec 2021 Next Renewal Due	59666.0171
CTM	COHEREX FLATSTENT	Registered	007589138	007589138	10	Feb-9-2009	Oct-21-2009	Coherex Medical, Inc.	9 Feb 2019 Next Renewal Due	59666.0115 CTM
CTM	COHEREX MEDICAL	Registered	007588874	007588874	10	Feb-9-2009	Oct-21-2009	Coherex Medical, Inc.	9 Feb 2019 Next Renewal Due	59666.0111 CTM
CTM	COHEREX WAVECREST	Registered	009879537	009879537	10	Apr-8-2011	Sep-12-2011	Coherex Medical, Inc.	8 Apr 2021 Next Renewal Due	59666.0161
Japan	COHEREX WAVECREST	Registered	2011-025032	5440834	10	Apr-8-2011	Sep-22-2011	Coherex Medical, Inc.	22 Sep 2021 Next Renewal Due	59666.0166
Mexico	COHEREX FLATSTENT	Registered	1024452	1139289	10	Aug-4-2009	Jan-25-2010	Coherex Medical, Inc.	04 Aug 2019 Next Renewal Due	59666.0118
Mexico	COHEREX MEDICAL	Registered	1,024,455	1139290	10	Aug-4-2009	Jan-25-2010	Coherex Medical, Inc.	04 Aug 2019 Next Renewal Due	59666.0114
Mexico	COHEREX WAVECREST	Registered	1171862	1238830	10	Apr-15-2011	Sep-21-2011	Coherex Medical, Inc.	15 Apr 2021 Next Renewal Due	59666.0170

Coherex Trademark Report

COUNTRY	TRADEMARK	STATUS	APP #	REG #	CLASS	APP DATE	REG DATE	OWNER	DEADLINE	H&H FILE NO.
New Zealand	COHEREX FLATSTENT	Registered	808059	808059	10	Jun-16-2009	Feb-9-2009	Coherex Medical, Inc.	09 Feb 2019 Next Renewal Due	59666.0105
New Zealand	COHEREX MEDICAL	Registered	808058	808058	10	Jun-16-2009	Sep-9-2010	Coherex Medical, Inc.	09 Feb 2019 Next Renewal Due	59666.0100
New Zealand	COHEREX WAVECREST	Registered	839950	839950	10	Apr-8-2011	Oct-10-2011	Coherex Medical, Inc.	8 Apr 2021 Next Renewal Due	59666.0165
Norway	COHEREX FLATSTENT	Registered	200906123	252350	10	Jun-17-2009	Sep-7-2009	Coherex Medical, Inc.	17 Jun 2019 Next Renewal Due	59666.0103
Norway	COHEREX MEDICAL	Registered	200906189	252519	10	Jun-19-2009	Sep-16-2009	Coherex Medical, Inc.	19 Jun 2019 Next Renewal Due	59666.0098
Norway	COHEREX WAVECREST	Registered	201104048	261550	10	Apr-8-2011	Sep-19-2011	Coherex Medical, Inc.	8 Apr 2021 Next Renewal Due	59666.0162
Switzerland	COHEREX FLATSTENT	Registered	56711/2009	593449	10	Jun-18-2009	Nov-18-2009	Coherex Medical, Inc.	18 Jun 2019 Next Renewal Due	59666.0104
Switzerland	COHEREX MEDICAL	Registered	56712/2009	593450	10	Jun-18-2009	Nov-18-2009	Coherex Medical, Inc.	18 Jun 2019 Next Renewal Due	59666.0099
Switzerland	COHEREX WAVECREST	Registered	54339/2011	617822	10	Apr-8-2011	Aug-10-2011	Coherex Medical, Inc.	8 Apr 2021 Next Renewal Due	59666.0163

**Schedule 3  
to  
Intellectual Property Security Agreement**

**US Patents**

[See attached]

## CohereX Technology

### Patents

CohereX Matter No./ H&H Ref. No.	Title	Filing Date	App. No. / Patent No.	App. Type	Status <u>(Deadline dates within next 6 months underlined)</u>
P4.1.US	Medical Device For Modification of LAA and Related Systems and Methods	Oct. 17, 2008	12/253,831 8,845,711	U.S. Utility	U.S. Patent No. 8,845,711, issued Sept. 30, 2014 Maintenance Fee Due March 30, 2018
P4.5.1.US	Medical Device For Modification of LAA and Related Systems and Methods	January 8, 2010	12/684,764 8,690,911	U.S. Utility	U.S. Patent No. 8,690,911, issued April 8, 2014 Maintenance Fee Due Oct. 8, 2017
P4.5.2.US	Medical Device For Modification of LAA and Related Systems and Methods	January 8, 2010	12/684,783 8,795,328	U.S. Utility	U.S. Patent No. 8,795,328, issued Aug. 5, 2014 Maintenance Fee Due Feb. 5, 2018
P4.5.3.US	Medical Device For Modification of LAA and Related Systems and Methods	January 8, 2010	12/684,795 8,840,641	U.S. Utility	U.S. Patent No. 8,840,641, issued Sept. 23, 2014 Maintenance Fee Due March 23, 2018
P4.10.2.US	Medical Device For Modification of LAA and Related Systems and Methods	June 17, 2010	12/818,046 8,636,764	U.S. Utility	U.S. Patent No. 8,636,764, issued Jan. 28, 2014 Maintenance Fee Due July 28, 2017
P4.10.3.US	Medical Device For Modification of LAA and Related Systems and Methods	June 17, 2010	12/818,053 8,715,318	U.S. Utility	U.S. Patent No. 8,715,318, issued May 6, 2014 Maintenance Fee Due Nov. 6, 2017
P3.1.3.US	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug. 8, 2007	11/836,037 8,979,941	U.S. Utility	U.S. Patent No. 8,979,941, issued March 17, 2015 Maintenance Fee Due Sept. 17, 2018
P3.1.4.US	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug. 8, 2007	11/836,051 8,840,655	U.S. Utility	U.S. Patent No. 8,840,655, issued Sept. 23, 2014 Maintenance Fee Due March 23, 2018
P3.1.5.US	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug. 8, 2007	11/836,013 8,864,809	U.S. Utility	U.S. Patent No. 8,864,809, issued Oct. 21, 2014 Maintenance Fee Due April 21, 2018

P3.1.7US	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug. 8, 2007	11/836,123 8,167,894	U.S. Utility	U.S. Patent No. 8,167,894, issued May 1, 2012 Maintenance Fee Due Nov. 1, 2015
P3.1.10US	Devices for Reducing the Size of an Internal Tissue Opening	May 19, 2010	12/783,498 8,529,597	U.S. Utility	U.S. Patent No. 8,529,597, issued Sept. 10, 2013 Maintenance Fee Due March 10, 2017
P2.2US	PFO Closure Device and Methods for Determining RF Dose for PFO closure	Feb. 5, 2007	11/671,428 8,221,405	U.S. Utility	U.S. Patent No. 8,221,405, issued July 17, 2012 Maintenance Fee Due January 17, 2016
P2.5US	Methods, Systems, and Devices for Sensing, Measuring, and Controlling Closure of a PFO	May 29, 2007	11/754,978 8,402,974	U.S. Utility	U.S. Patent No. 8,402,974, issued March 26, 2013 Maintenance Fee Due Sept. 26, 2016
P7.2US	Systems and Methods for Reduction of Atrial Fibrillation	Jan. 23, 2009	12/359,223 8,235,988	U.S. Utility	U.S. Patent No. 8,235,988, issued Aug. 7, 2012 Maintenance Fee Due Feb. 7, 2016
P7.2.1US	Systems and Methods for Reduction of Atrial Fibrillation	Aug. 6, 2012	13/567,597 8,636,732	U.S. Utility	U.S. Patent No. 8,636,732, issued Jan. 28, 2014 Maintenance Fee Due July 28, 2017
P7.2.2US	Systems and Methods for Reduction of Atrial Fibrillation	Dec. 30, 2013	14/143,913 9,044,233	U.S. Utility	U.S. Patent No. 9,044,233, issued June 2, 2015 Maintenance Fee Due December 2, 2018
P10.1US	Method and Apparatus for Connecting a Ventricular Assist Device to a Heart	May 5, 2009	12/436,056 8,235,885	U.S. Utility	U.S. Patent No. 8,235,885, issued August 7, 2012 Maintenance Fee Due Feb. 7, 2016
P10.2US	Method and Apparatus for Connecting a Ventricular Assist Device to a Heart	Nov. 2, 2010	12/938,030 8,540,616	U.S. Utility	U.S. Patent No. 8,540,616, issued September 24, 2013 Maintenance Fee Due March 24, 2017
P10.1.1US	Ventricular Assist Device and Related Methods	Aug. 6, 2012	13/567,824 8,579,791	U.S. Utility	U.S. Patent No. 8,579,791, issued November 12, 2013 Maintenance Fee Due May 12, 2017
P10.2.1US	Ventricular Assist Device and Related Methods	Sept. 23, 2013	14/034,332 8,845,509	U.S. Utility	U.S. Patent No. 8,845,509, issued September 30, 2014 Maintenance Fee Due March 30, 2018

**Schedule 4  
to  
Intellectual Property Security Agreement**

**US Patent Applications**

[See attached]



Patent Applications

Coherex Matter No. / H&H Ref. No.	Title	Filing Date	App. No. / Patent No.	App. Type	Status (Deadline dates within next 6 months <u>underlined</u> )
P4.10.1US	Medical Device For Modification of LAA and Related Systems and Methods	June 17, 2010	12/818,041	U.S. Utility	Office Action dated July 13, 2015 Response Due <u>Oct. 13, 2015</u> (3 month)
P4.10.4US	Medical Device For Modification of LAA and Related Systems and Methods	June 17, 2010	12/818,059	U.S. Utility	Pending, awaiting action from the USPTO
P4.10.5US	Medical Device and Delivery System for Modification of LAA and Methods Thereof	April 19, 2012	13/450,755	U.S. Utility	Office Action dated May 5, 2015 Response Due <u>Aug. 5, 2015</u> (3 month)
P4.10.7US	Medical Device For Modification of LAA and Related Systems and Methods	November 1, 2012	13/666,612	U.S. Utility	Office Action dated May 6, 2015 Response Due <u>Aug. 6, 2015</u> (3 month)
P4.10.8US	Medical Device For Modification of LAA and Related Systems and Methods	June 18, 2014	14/308,695	U.S. Utility	Pending, awaiting action from the USPTO
P4.10.9Prov	Medical Device For Modification of LAA and Related Systems and Methods	April 16, 2015	62/148,317	U.S. Utility – Provisional	Conversion to Non-Provisional Due: April 16, 2016
P4.10.2.1US	Medical Device For Modification of LAA and Related Systems and Methods	January 24, 2014	14/163,925	U.S. Utility	Pending, awaiting action from the USPTO
P4.5.1.1US	Medical Device For Modification of LAA and Related Systems and Methods	March 17, 2014	14/215,266	U.S. Utility	Continuation of P4.10.2US Office Action dated July 21, 2015 Response Due <u>Oct. 21, 2015</u> (3 month)
P4.5.2.1US	Medical Device For Modification of LAA and Related Systems and Methods	May 26, 2014	14/287,103	U.S. Utility	Continuation of P4.5.1US Pending, awaiting action from USPTO
P4.1.1US	Medical Device For Modification of	Sept. 16,	14/487,885	U.S. Utility	Continuation of P4.5.2US Pending, awaiting action from USPTO

	LAA and Related Systems and Methods	2014				Continuation of P4.1US
P3.1.1US	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug. 8, 2007	11/836,000	U.S. Utility		Notice of Allowance dated June 2, 2015 Issue Fee Due <u>September 2, 2015</u>
P3.1.2US	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug. 8, 2007	11/836,016	U.S. Utility		Pending, awaiting action from USPTO
P3.1.10.1US	Devices for Reducing the Size of an Internal Tissue Opening	Sept. 10, 2013	14/023,462	U.S. Utility		Response to Restriction Requirement due <u>Oct. 5, 2015</u>
P7.2.3US	Systems and Methods for Reduction of Atrial Fibrillation	May 18, 2015	14/715,338	U.S. Utility		Pending, awaiting action from USPTO
P10.2.2US	Ventricular Assist Device and Related Methods	Sept. 29, 2014	14/500,811	U.S. Utility		Pending, awaiting action from USPTO

**Schedule 5  
to  
Intellectual Property Security Agreement**

**PCT Patent Applications**

None

**Schedule 6**  
**to**  
**Intellectual Property Security Agreement**  
**Foreign Patents and Foreign Patent Applications**

[See attached]

Foreign Patents and Foreign Patent Applications

Coherex Matter No./ H&H Ref. No.	Title	Filing Date	App. No. / Patent No.	App. Type	Status (Deadline dates within next 6 months <u>underlined</u> )
P4.10.1EP 59666.0176	Medical Device For Modification of LAA	June 17, 2010	10728982.9	European Utility	Response to Office Action Filed in April 2013.
P4.10.1CA 59666.0177	Medical Device For Modification of LAA	June 17, 2010	2,765,682	Canadian Utility	Examination Requested on 6/17/2015.
P4.10.1AU 59666.0178	Medical Device For Modification of LAA	June 17, 2010	2010262859	Australian Utility	Examination Requested on 8/8/14.
P4.10.1JP 59666.0180	Medical Device For Modification of LAA	June 17, 2010	2012-516313	Japanese Utility	Issue Fee Paid February 2015.
P4.10.1CN 59666.0179	Medical Device For Modification of LAA	June 17, 2010	201080035094.6	Chinese Utility	Response to Office Action due <u>September 6, 2015</u> .
P4.10.1EP2 59666.0191	Medical Device for Modification of Left Atrial Appendage and Related Systems and Methods	11/1/2012	12791353.1	European Utility	Response to Office Action filed December 2014.
P4.10.1JP2 59666.0192	Medical Device for Modification of Left Atrial Appendage and Related Systems and Methods	11/1/2012	2014-540090	Japanese Utility	Examination Request due <u>November 1, 2015</u> .
P4.10.1CN2 59666.0193	Medical Device for Modification of Left Atrial Appendage and Related Systems and Methods	11/1/2012	201280064209.3	Chinese Utility	Examination Requested September 2014.
P4.10.1JP3 59666.0197	Medical Device For Modification of LAA	2/12/2015	2015-025634	Japanese Utility	Divisional of 59666.0180 (JP Pat. App. No. 2012-516313) filed in Feb. 2015
P3.1.7JP	Methods, Systems and Devices for Reducing the Size of an Internal Tissue Opening	Aug: 9, 2007	2009-524000 5334850	Japanese Utility	Issued – Pat. No. 5334850 (next annuity fee due 8-9-2016)

PATENT

REEL: 036332 FRAME: 0924

RECORDED: 08/14/2015